Company / R&D Expense
BeOne Medicines Ltd. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$2.1B
FY2025
5-year range
$1.5B / $2.1B
FY2021-FY2025
Trend
+9.9%
vs FY2024
Sector context
#11 of 210
Health Care
What the data says
Among 210 Health Care companies, BeOne Medicines Ltd. is in the top 5% for r&d expense. R&D Expense has increased for 9 consecutive years, from $98M in FY2016 to $2.1B in FY2025.
Based on SEC 10-K filings.
$2.1B in FY2025 with a 5-year CAGR of +10.6%. Top quartile in the Health Care sector.
Improved from $1.8B to $2.1B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +9.4%
- 5-Year CAGR
- +10.6%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 210This company $2.1B Sector average $644.0M
▼
+233.2% above sector average
Key checks
Key Insights
- BeOne Medicines Ltd.'s r&d expense has grown for 9 consecutive years.
- 5-year CAGR of +10.6%, indicating consistent growth.
- In FY2025, r&d expense increased 9.9% year-over-year.
- Ranks #11 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1B | +9.9% |
| FY2024 | $2.0B | +9.8% |
| FY2023 | $1.8B | +8.4% |
| FY2022 | $1.6B | +12.4% |
| FY2021 | $1.5B | +12.7% |
| FY2020 | $1.3B | +39.6% |
| FY2019 | $927.3M | +36.6% |
| FY2018 | $679.0M | +152.4% |
| FY2017 | $269.0M | +174.4% |
| FY2016 | $98.0M | +68.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026